Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Open accessThe DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index; 39 of the 112 sources its claims cite were checked for support.
Abstract
Drug resistance is perhaps the greatest challenge in improving outcomes for cancer patients undergoing treatment with targeted therapies. It is becoming clear that “persisters,” a subpopulation of drug-tolerant cells found in cancer populations, play a critical role in the development of drug resistance. Persisters are able to maintain viability under therapy but are typically slow cycling or dormant. These cells do not harbor classic drug resistance driver alterations, and their partial resistance phenotype is transient and reversible upon removal of the drug. In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy. Thus, eliminating persister cells will be crucial to improve outcomes for cancer patients. Using lung cancer targeted therapies as a primary paradigm, this review will give an overview of the characteristics of drug-tolerant persister cells, mechanisms associated with drug tolerance, and potential therapeutic opportunities to target this persister cell population in tumors.
Overview
CoChat Summary
TL;DR
This review argues that drug-tolerant persister cells survive targeted therapy without bona fide resistance mutations, are often slow-cycling/dormant, and can serve as a reservoir from which acquired resistance evolves. It summarizes mechanisms of tolerance and potential therapeutic vulnerabilities, using lung cancer targeted therapies as the primary paradigm.
Key findings
- In the founding cancer persister study, ~0.3% of PC9 EGFR-mutant NSCLC cells survived lethal-dose erlotinib as slowly cycling drug-tolerant persisters; upon drug removal, expanded persisters reverted to a drug-sensitive state.
- Acquired resistance can evolve from persisters: in PC9 pools treated with gefitinib, 5–10% developed rapid EGFR T790M resistance as early as 2 weeks, while most underwent initial response followed by slow expansion of drug-tolerant cells and later full resistance.
- Clinical resistance mechanisms include secondary mutations such as EGFR T790M, bypass signaling such as MET activation in 5–10% of EGFR TKI-resistant lung cancers, and lineage transformation in 5–15% of EGFR-mutant lung cancer patients with acquired resistance.
- Persister mechanisms reviewed include epigenetic/chromatin reprogramming, bypass/alternative signaling, apoptosis suppression, metabolic reprogramming, tumor microenvironment interactions, and adaptive mutagenesis; clinical minimal residual disease is the closest analogue.
Methods
- Narrative review of in vitro, in vivo, and clinical studies on drug-tolerant persister cells, focused on targeted therapies for solid malignancies and using lung cancer as the primary paradigm.
- Synthesizes mechanistic studies and includes Table 1 cataloging tumor type, target oncogene, targeted therapy, model system, mechanism of drug tolerance, and susceptibility for each study.
- No systematic review, meta-analysis, or primary experimental methods are reported.
Limitations
- The paper states that understanding clinical persisters is limited by difficulty accessing tumor tissue at minimal residual disease, that molecular signatures indicating whether relapsed tumors passed through a persister state are undefined, and that the true extent of relapse from persister evolution versus pre-existing resistant clones remains unknown.
- The paper states that tumor microenvironment contributions cannot be addressed well by in vitro models or in vivo studies using immunocompromised mice, and that future work should prioritize on-treatment biopsies.
- Evident from the text: this is a narrative review without systematic search or quantitative synthesis, so conclusions depend on the selected literature and model systems discussed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
21 Valid · 0 Not valid · 88 Not checked · 30 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results revealed a large fraction of shared barcodes within the cells treated with EGFR inhibitor alone, consistent with selection of pre-existing persister clones.”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.3. Origin of Drug-Tolerant Persister Cells
What the sources say
- Supportedcites [56] Kurppa K.J. Liu Y. To C. Zhang T. Fan M. Vajdi A. Knelson E.H. Xie Y. Lim K. Cejas P. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway Cancer Cell 2020 37 104 122.e112 10.1016/j.ccell.2019.12.006 31935369 PMC7146079 source
The Results section (“Combined EGFR and MEK inhibition results in a stable, but reversible dormant state”; page not supplied) reports DNA barcoding of PC-9 cells and a large fraction of shared barcodes after gefitinib or osimertinib alone. The authors interpret this as strong evidence for selection of pre-existing clones. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Alternatively, cells may survive initial drug treatment by epigenetic adaptations that enable a drug-tolerant, slow-cycling phenotype that precedes the emergence of permanent drug resistance [23,24].”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 1. Introduction
What the sources say
- Supportedcites [23] Sharma S.V. Lee D.Y. Li B. Quinlan M.P. Takahashi F. Maheswaran S. McDermott U. Azizian N. Zou L. Fischbach M.A. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 2010 141 69 80 10.1016/j.cell.2010.02.027 20371346 PMC2851638 source
The Abstract and Introduction of Sharma et al. (2010) describe a reversibly drug-tolerant subpopulation maintained via an altered chromatin state requiring RBP2/KDM5A, i.e. an epigenetic adaptation, and the Results (p. 'Detection of a drug-tolerant cancer cell subpopulation') characterize the DTPs as 'largely quiescent' slow-cycling cells surviving an otherwise lethal exposure. The DISCUSSION states explicitly that such a transient drug-tolerant state lets a small subpopulation withstand the initial drug onslaught 'until more permanent resistance mechanisms can be established,' matching the claim's ordering of tolerance preceding permanent resistance. The claim's hedged wording ('may') is consistent with the source's own framing. (LLM, conf=0.93)
- Not checked yetcites [24] Guler G.D. Tindell C.A. Pitti R. Wilson C. Nichols K. KaiWai Cheung T. Kim H.J. Wongchenko M. Yan Y. Haley B. Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure Cancer Cell 2017 32 221 237 10.1016/j.ccell.2017.07.002 28781121 source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.3. Origin of Drug-Tolerant Persister Cells
What the sources say
- Supportedcites [56] Kurppa K.J. Liu Y. To C. Zhang T. Fan M. Vajdi A. Knelson E.H. Xie Y. Lim K. Cejas P. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway Cancer Cell 2020 37 104 122.e112 10.1016/j.ccell.2019.12.006 31935369 PMC7146079 source
The Results section reports that entry into dormancy after EGFR/MEK inhibitor treatment was predominantly stochastic rather than selection of a pre-existing resistant clone. The Discussion describes cells reversibly adopting a dormant, senescent-like state during treatment and returning to their prior state after drug withdrawal. Together, these passages support the claim that some persister phenotypes arise through treatment-induced plasticity. Page numbers are unavailable in our copy. (LLM, conf=0.92)
- Supportedcites [64] Goldman A. Majumder B. Dhawan A. Ravi S. Goldman D. Kohandel M. Majumder P.K. Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition Nat. Commun. 2015 6 6139 10.1038/ncomms7139 25669750 PMC4339891 source
In Results, ‘Drug-induced phenotypic plasticity and tolerance’ (page not provided), the paper identifies drug-tolerant cells as persisters and reports that low-dose chemotherapy induced a CD44HiCD24Hi phenotype without selecting for surviving cells. It concludes that chemotherapy tolerance could arise from a drug-induced cell-state transition, matching the claim’s cautious wording. (LLM, conf=0.93)
- Partly supportedcites [65] Glasspool R.M. Teodoridis J.M. Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance Br. J. Cancer 2006 94 1087 1092 10.1038/sj.bjc.6603024 16495912 PMC2361257 sourceExperimental — accuracy not yet measured
The ‘Genetic vs Epigenetic Alterations of Resistance Genes’ section suggests that epigenetic changes allow tumour cells to adapt to cytotoxic drug therapy and produce persistent acquired resistance. It does not identify these cells as persisters or establish that persister phenotypes arise through treatment-induced plasticity. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Over time, a fraction of DTPs reinitiated proliferation in the presence of erlotinib, giving rise to a second population of cells labeled drug-tolerant expanded persisters (DTEPs).”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.2. Persisters in Cancer
What the sources say
- Supportedcites [23] Sharma S.V. Lee D.Y. Li B. Quinlan M.P. Takahashi F. Maheswaran S. McDermott U. Azizian N. Zou L. Fischbach M.A. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 2010 141 69 80 10.1016/j.cell.2010.02.027 20371346 PMC2851638 source
The Results section 'Detection of a drug-tolerant cancer cell subpopulation' (p. 1 of our copy) states that although DTPs are largely quiescent, approximately 20% eventually resume normal proliferation in the presence of drug, yielding colonies termed 'drug-tolerant expanded persisters' (DTEPs), which can be propagated indefinitely in drug. The 'Generation of DTEPs' procedures (Experimental Procedures) corroborate that clones of drug-resistant cells appear after ~30 days of continued erlotinib/gefitinib selection. Both the fraction ('a fraction') and the continued-drug condition in the citing sentence match the source. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Some studies indicate that drug-tolerant persister populations or cancer cells that are primed to persist exist even prior to treatment [40,43,60,61].”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 2. Origins and Characteristics of Persisters > 2.3. Origin of Drug-Tolerant Persister Cells
What the sources say
- Supportedcites [40] Hangauer M.J. Viswanathan V.S. Ryan M.J. Bole D. Eaton J.K. Matov A. Galeas J. Dhruv H.D. Berens M.E. Schreiber S.L. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition Nature 2017 551 247 250 10.1038/nature24297 29088702 PMC5933935 source
The passage on RSL3 pretreatment (labeled Abstract in our copy; page not provided) says that reducing the later persister-cell pool is consistent with reports that persister cells may preexist drug treatment. This supports the citing sentence’s qualified claim that some studies indicate pretreatment existence. (LLM, conf=0.93)
- Supportedcites [43] Raha D. Wilson T.R. Peng J. Peterson D. Yue P. Evangelista M. Wilson C. Merchant M. Settleman J. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation Cancer Res. 2014 74 3579 3590 10.1158/0008-5472.CAN-13-3456 24812274 source
In “Drug-tolerant cancer cells express the CSC marker ALDH1A1,” the paper identifies ALDH-high cells before treatment and reports that they showed greater crizotinib tolerance than ALDH-low cells. The Discussion explicitly describes a preexisting subpopulation with characteristics of drug-tolerant cells. This supports the citing sentence’s qualified claim that some cancer cells are primed to persist before treatment. (LLM, conf=0.93)
- Supportedcites [60] Roesch A. Vultur A. Bogeski I. Wang H. Zimmermann K.M. Speicher D. Korbel C. Laschke M.W. Gimotty P.A. Philipp S.E. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells Cancer Cell 2013 23 811 825 10.1016/j.ccr.2013.05.003 23764003 PMC3810180 source
In Results (“Dynamics of the therapy-resistant JARID1Bhigh phenotype”; page unavailable), the authors conclude that treatment mainly selects pre-existing slow-cycling JARID1Bhigh melanoma cells. This supports the claim that cells primed to survive treatment can exist beforehand, while the paper also allows that some cells may acquire the phenotype. (LLM, conf=0.93)
- Supportedcites [61] Shaffer S.M. Dunagin M.C. Torborg S.R. Torre E.A. Emert B. Krepler C. Beqiri M. Sproesser K. Brafford P.A. Xiao M. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance Nature 2017 546 431 435 10.1038/nature22794 28607484 PMC5542814 source
The Abstract says that transcriptional variability in melanoma cells before treatment predicts which cells will resist the drug. It describes rare cells in a transient pre-resistant state that become stably resistant after drug-induced reprogramming, supporting the claim's 'primed to persist' alternative. (LLM, conf=0.92)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 13 with their cited sources checked
Create a free account to see all 139 claims and to verify the 73 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in BRAF-mutated CRC, the response to single-agent BRAF inhibition is limited by EGFR-mediated adaptive feedback reactivation of MAPK signaling [237].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [237]
In the citing paper
“Biologically, the closest analogy to clinical residual disease is the drug-tolerant (or “persister”) state (9).”
From Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer (2023) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 3. Drug-Tolerant Persister Cells: Mechanisms of Drug Tolerance and Therapeutic Vulnerabilities > 3.1. Epigenetic Reprogramming/Plasticity
“| Melanoma | BRAF | Vemurafenib | SK-MEL-5, SK-MEL-28, G-361 | Stromal cell secretion of HGF | MAPK (PD184352), PI3K–AKT (crizotinib, MK-2206) | [99] |”
§ Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer > 3. Drug-Tolerant Persister Cells: Mechanisms of Drug Tolerance and Therapeutic Vulnerabilities > 3.5. Interactions with the Tumor Microenvironment
“Using either an HGF-blocking antibody or the MET small molecule inhibitor crizotinib to target the HGF–MET axis suppressed fibroblast-mediated resistance.”
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 2×
“Drug resistance to targeted therapies in cancer can be classified as primary or acquired (Figure 1A) [8,9].”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 4×
“For example, the discovery of MET amplification in a subset of resistant EGFR-mutant lung cancers [14] has now led to promising activity of combination EGFR and MET TKIs [103] in EGFR-mutant lung cancer patients with acquired resistance due to MET amplification.”
BackgroundInfluentialEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · cited 1×
“For example, in EGFR-mutant lung cancers, the point mutation leading to a substitution of methionine for threonine at amino acid position 790 in exon 20 of EGFR, known as the EGFR T790M gatekeeper mutation, is a leading cause of resistance to first- and second-generation EGFR inhibitors [11,12].”
BackgroundGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Bacterial Persistence as a Phenotypic Switch
Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L., & Leibler, S. (2004) · Science · doi:10.1126/science.1099390 · Cited by 2,952 · cited 1×
“More recently, live imaging experiments have confirmed that these bacterial cells that survived antibiotic treatment were indeed not proliferating before the addition of antibiotics [30].”
BackgroundOverall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770 · cited 12×
“Cancers 2021, 13, 2666 4 of 26a cers , , x FOR PEER REVIEW 4 of 31 The notion of persisters was extended to the cancer field in 2010 by Settleman and colleagues to describe cancer cells treated with targeted therapies [Sharma et al., 2010].”
BackgroundInfluentialEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545 · cited 1×
“For instance, epithelial-to-mesenchymal transition (EMT) is a phenotype switching event induced by targeted therapy in various tumors that has been linked to drug tolerance and/or resistance [78,79].”
BackgroundEMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“For an excellent review on cancer stem cells and anticancer drug resistance, we refer the reader to an excellent review by Shibue and Weinberg [59].”
BackgroundA restricted cell population propagates glioblastoma growth after chemotherapy
Chen, J., Li, Y., Yu, T.-S., McKay, R. M., Burns, D. K., Kernie, S. G., & Parada, L. F. (2012) · Nature · doi:10.1038/nature11287 · Cited by 2,354 · cited 1×
“In cancer, the term “persister” has no clear biological definition and the term is used interchangeably with other terms such as tolerant [23,25,40], dormant [52], or quiescent [53] to refer to sub-populations of cancer cells that survive prolonged drug treatment [54].”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 2×
“These included enzymes such as NADH dehydrogenase and ATP synthase, which regulate oxidative phosphorylation, and pharmacologic blockade of the mitochondrial respiratory chain with ATP synthase inhibitors or complex inhibitors decreased JARID1B expression and promoted long-term growth inhibition in vitro.”
BackgroundUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 2×
“Colon cancer BRAF Vemurafenib VACO432, SNUC5, HT29, KM20, WiDr; xenografts EGFR-mediated feedback activation EGFR (cetuximab, gefitinib, or erlotinib) [95]”
BackgroundDependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Hangauer, M. J., Viswanathan, V. S., Ryan, M. J., Bole, D., Eaton, J. K., Matov, A., Galeas, J., Dhruv, H. D., Berens, M. E., Schreiber, S. L., et al. (2017) · Nature · doi:10.1038/nature24297 · Cited by 1,799
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 5×
“Through their ability to activate receptor tyrosine kinases and the same downstream signaling pathways as the targeted oncogene, many soluble growth factors have the ability to oppose the effects of a range of targeted therapies [16,99].”
BackgroundInfluentialVemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Distinguishing between resistance, tolerance and persistence to antibiotic treatment
Brauner, A., Fridman, O., Gefen, O., & Balaban, N. Q. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.34 · Cited by 1,612 · cited 1×
“In microbiology, resistance is defined as the inherent ability of bacteria to grow at high concentrations of antibiotics and typically results from genetic mutations [49].”
BackgroundCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · cited 1×
“Interestingly, targeted therapies such as EGFR inhibitors and CDK4/6 inhibitors can induce a strong reactivation of repeated elements in cancer cells, which results in cell death [24,102].”
BackgroundStochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340 · cited 1×
“Tumors can display a constantly evolving epigenetic landscape that involves altered DNA promoter regions shifts, deregulated histone protein acetylation or methylation, or dysregulated expression of repetitive elements [70].”
BackgroundOncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · cited 2×
“In cancer, the term “persister” has no clear biological definition and the term is used interchangeably with other terms such as tolerant [23,25,40], dormant [52], or quiescent [53] to refer to sub-populations of cancer cells that survive prolonged drug treatment [54].”
BackgroundPersistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243 · cited 1×
“Moreover, upon drug withdrawal, these drug-tolerant slow-cycling bacteria that survived antibiotic treatment can revert to a proliferative state and re-establish a drug sensitive population, demonstrating that bacterial drug persistence is transient and mediated by phenotypic plasticity rather than genetic alterations…”
BackgroundActivation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224 · cited 2×
“found increased AXL activation and evidence for EMT in several in vitro and in vivo EGFRmutant NSCLC models with acquired resistance to erlotinib [87].”
BackgroundRare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218 · cited 4×
“Some studies indicate that drugtolerant persister populations or cancer cells that are primed to persist exist even prior to treatment [40,43,60,61].”
BackgroundInfluentialTranscriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194 · cited 1×
“Changes in global chromatin architecture can lead to remodeling of enhancers and super-enhancers that control transcriptional programs, leading to a state of transcriptional dependency or addiction [73].”
BackgroundTREATMENT OF STAPHYLOCOCCAL INFECTIONS WITH PENICILLIN BY INTERMITTENT STERILISATION
Bigger, J. (1944) · The Lancet · doi:10.1016/s0140-6736(00)74210-3 · Cited by 1,178 · cited 1×
“The surviving bacterial cells were later characterized and named “bacterial persisters” in 1944 by Joseph Bigger, who hypothesized that their survival resulted from slow cell cycle rates rather than innate heritable resistance mechanisms [34].”
BackgroundRoesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., & Herlyn, M. (2010) · Cell · doi:10.1016/j.cell.2010.04.020 · Cited by 1,158 · cited 4×
“Indeed, knockdown of KDM5A or treatment with histone deacetylase (HDAC) inhibitors reduced the survival of persister cells.”
BackgroundInfluentialWidespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 4×
“By analogy, activation of receptor tyrosine kinase bypass signaling pathways by exogenous growth factors can decrease the dependence of cancer cells on the targeted oncogene and facilitate drug tolerance [16].”
BackgroundInfluentialAlveolar progenitor and stem cells in lung development, renewal and cancer
Desai, T. J., Brownfield, D. G., & Krasnow, M. A. (2014) · Nature · doi:10.1038/nature12930 · Cited by 1,060
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059 · cited 1×
“In experimental models of MET-driven acquired resistance, MET reactivates both PI3K/AKT and MEK/ERK signaling despite EGFR inhibition [14,15].”
BackgroundCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022 · cited 2×
“Colorectal cancer BRAF Vemurafenib HT-29 and WiDr; xenografts EGFR-mediated feedback activation EGFR (erlotinib) [96]”
BackgroundHata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985 · cited 6×
“Similarly, resistant clones that evolved from drug-tolerant cells and retained a partial mesenchymal phenotype showed decreased apoptotic response to third-generation EGFR inhibitors, and treatment with navitoclax restored sensitivity [25].”
BackgroundMethodSelf-citationAcquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Oser, M. G., Niederst, M. J., Sequist, L. V., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 942 · cited 1×
“, loss of both TP53 and RB1) are required for this phenotypic transformation to occur [18,19].”
BackgroundReversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature · doi:10.1038/nature13121 · Cited by 888
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor
Kwiatkowski, N., Zhang, T., Rahl, P. B., Abraham, B. J., Reddy, J., Ficarro, S. B., Dastur, A., Amzallag, A., Ramaswamy, S., Tesar, B., et al. (2014) · Nature · doi:10.1038/nature13393 · Cited by 855 · cited 1×
“Other studies have demonstrated that targeting RNA polymerase II-mediated transcription with the CDK7/12 inhibitor THZ1 [76] synergizes with various targeted therapies to suppress drug-tolerant persister cells [77], further supporting a role for transcriptional adaptation in the establishment of the DTP state.”
BackgroundTherapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · cited 1×
“Unlike treatment-induced senescence that occurs as a result of DNA-damaging chemotherapeutic agents, cancer cells seem to exhibit the reversible drug-tolerant state most commonly upon treatment with targeted therapy [57].”
BackgroundToward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761 · cited 1×
“Stochastic gene expression across the population could contribute to phenotypic heterogeneity that at the time of treatment initiation determines which cells will survive long enough to reprogram a more stable resistance phenotype [68].”
BackgroundSingle-cell Wnt signaling niches maintain stemness of alveolar type 2 cells
Nabhan, A. N., Brownfield, D. G., Harbury, P. B., Krasnow, M. A., & Desai, T. J. (2018) · Science · doi:10.1126/science.aam6603 · Cited by 755
In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Döbbeling, U., Kobert, N., Schaerer, L., Hemmi, S., & Dummer, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2491 · Cited by 743 · cited 1×
“In melanoma, tumor cells treated with targeted therapy underwent a lineage transition to an undifferentiated mesenchymal cell state leading to drug tolerance and eventually resistance [48,80,81].”
BackgroundMok, T., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H. I., Ahn, J. S., Shaw, A. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.478 · Cited by 686
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.017 · Cited by 685
Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., Körbel, C., Laschke, M. W., Gimotty, P. A., Philipp, S. E., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.003 · Cited by 670 · cited 12×
“In melanoma, persister cells express elevated levels of KDM5 leading to slowing of cell cycle progression [60,72].”
BackgroundResultInfluentialLow MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications · doi:10.1038/ncomms6712 · Cited by 639
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Self-citationHirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., Larkin, J., Marais, R., & Sahai, E. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.008 · Cited by 593 · cited 3×
“The tumor microenvironment is a complex ecosystem comprised of multiple cell types that support the growth of tumor cells, facilitate tumor progression, and modulate therapeutic response to anti-cancer treatments [29,99,100,120,121].”
BackgroundCombined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583 · cited 1×
“, loss of both TP53 and RB1) are required for this phenotypic transformation to occur [18,19].”
BackgroundDiverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581 · cited 3×
“Subsequently, work by our group and others showed that clinical mechanisms of acquired resistance can occur by evolution of drug-tolerant persister cells during long term drug exposure [25,26].”
BackgroundDrug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555 · cited 3×
“found that transient STAT3 activation mediated by IL-6 and FGFR in response to oncogenic kinase inhibition significantly contributes to survival of several different oncogene-addicted cancer cell lines [67].”
BackgroundInfluentialRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Liau, B. B., Sievers, C., Donohue, L. K., Gillespie, S. M., Flavahan, W. A., Miller, T. E., Venteicher, A. S., Hebert, C. H., Carey, C. D., Rodig, S. J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2016.11.003 · Cited by 535 · cited 9×
“In melanoma, persister cells express elevated levels of KDM5 leading to slowing of cell cycle progression [60,72].”
BackgroundResultInfluentialStudying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Su, K.-Y., Chen, H.-Y., Li, K.-C., Kuo, M.-L., Yang, J. C.-H., Chan, W.-K., Ho, B.-C., Chang, G.-C., Shih, J.-Y., Yu, S.-L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3224 · Cited by 499
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · cited 2×
“Various cancers KRAS ARS-1620, AMG 510 KRAS G12C cell lines, xenograft RAS pathway feedback reactivation SHP2 (SHP099) [97]”
BackgroundKurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475 · cited 7×
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
BackgroundMethodInfluentialPiotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0399 · Cited by 458
Self-citationA melanocyte lineage program confers resistance to MAP kinase pathway inhibition
Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature · doi:10.1038/nature12688 · Cited by 452 · cited 1×
“4 Cell fate and lineage plasticity (high MITF expression) HDAC (panobinostat, vorinostat, or entinostat); forskolin and IBMX (FSK/I) [82]”
BackgroundObservations on the Mechanism of Action of Penicillin.
Hobby, G. L., Meyer, K., & Chaffee, E. (1942) · Experimental Biology and Medicine · doi:10.3181/00379727-50-13773 · Cited by 444 · cited 1×
“In 1942, Gladys Hobby observed that while penicillin was capable of killing the vast majority of cultured streptococcal cells, ~1% remained intact [33].”
BackgroundAdaptive mutability of colorectal cancers in response to targeted therapies
Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., et al. (2019) · Science · doi:10.1126/science.aav4474 · Cited by 433
Sequist, L. V., Han, J.-Y., Ahn, M.-J., Cho, B. C., Yu, H., Kim, S.-W., Yang, J. C.-H., Lee, J. S., Su, W.-C., Kowalski, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30785-5 · Cited by 421
Schoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411 · cited 2×
“A classic example of the third mechanism of acquired resistance—lineage transformation—is the histologic transformation of lung adenocarcinoma subtype to small cell carcinoma subtype, which accounts for 5–15% of EGFR-mutant lung cancer patients with acquired resistance to EGFR TKIs [12,17].”
BackgroundDormancy of Mammary Carcinoma After Mastectomy
Karrison, T. G., Ferguson, D. J., & Meier, P. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.80 · Cited by 407
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Bivona, T. G., Hieronymus, H., Parker, J., Chang, K., Taron, M., Rosell, R., Moonsamy, P., Dahlman, K., Miller, V. A., Costa, C., et al. (2011) · Nature · doi:10.1038/nature09870 · Cited by 396
Yao, Z., Fenoglio, S., Gao, D. C., Camiolo, M., Stiles, B., Lindsted, T., Schlederer, M., Johns, C., Altorki, N., Mittal, V., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009472107 · Cited by 389
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia
Knoechel, B., Roderick, J. E., Williamson, K. E., Zhu, J., Lohr, J. G., Cotton, M. J., Gillespie, S. M., Fernandez, D., Ku, M., Wang, H., et al. (2014) · Nature Genetics · doi:10.1038/ng.2913 · Cited by 367 · cited 1×
“Following the initial description by Settleman and colleagues, similar drug-tolerant persisters have been reported in many other cancer models, including lung cancer [35–40], melanoma [39–41], breast cancer [39,40,42], colon cancer [39], gastric cancer [43], ovarian cancer [40], leukemia [44], and glioblastoma [45].”
ResultAXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Taniguchi, H., Yamada, T., Wang, R., Tanimura, K., Adachi, Y., Nishiyama, A., Tanimoto, A., Takeuchi, S., Araujo, L. H., Boroni, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08074-0 · Cited by 356 · cited 2×
“Osimertinib PC9 AXL kinase signaling AXL (NPS1034) [92]”
BackgroundAn inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells
Vinogradova, M., Gehling, V. S., Gustafson, A., Arora, S., Tindell, C. A., Wilson, C., Williamson, K. E., Guler, G. D., Gangurde, P., Manieri, W., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2085 · Cited by 351 · cited 9×
“Upregulation of histone demethylases (KDMs) leads to changes in the methylation of histone3 lysine (H3K) residues, as well as deregulation of a variety of cellular functions [39].”
BackgroundResultInfluentialSorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Méndez-Blanco, C., Fondevila, F., García-Palomo, A., González-Gallego, J., & Mauriz, J. L. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0159-1 · Cited by 339
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320
Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3456 · Cited by 307 · cited 6×
“Some studies indicate that drugtolerant persister populations or cancer cells that are primed to persist exist even prior to treatment [40,43,60,61].”
BackgroundResultInfluentialTranscriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4
Zanconato, F., Battilana, G., Forcato, M., Filippi, L., Azzolin, L., Manfrin, A., Quaranta, E., Di Biagio, D., Sigismondo, G., Guzzardo, V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0158-8 · Cited by 306 · cited 1×
“BET proteins such as BRD4 have been shown to be targeted to specific areas of the genome by interaction with other DNA-binding proteins such as YAP/TAZ to enforce transcriptional addiction in cancer cells [75].”
BackgroundWang, W., Li, Q., Yamada, T., Matsumoto, K., Matsumoto, I., Oda, M., Watanabe, G., Kayano, Y., Nishioka, Y., Sone, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1001 · Cited by 297
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288 · cited 1×
“Epigenetic reprogramming may be of central importance when drug-resistant states are functionally heterogeneous, evolving, and transient [69], in contrast to more stable drug resistance resulting from genetic alterations.”
BackgroundShah, K. N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Wang, V. E., Hemmati, G., Martins, M. M., Maynard, A., Kuhn, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0264-7 · Cited by 286 · cited 2×
“Osimertinib, rociletinib PC9, HCC827, HCC4006, and NCI-H1975 AURKA signaling AURKA (MLN8237) [94]”
BackgroundGuler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277 · cited 7×
“NSCLC EGFR Gefitinib PC9 Repressed chromatin state (KDM5 upregulation; H3K9 methylation-dependent LINE-1 elements) HDAC (trichostatin) [23,24]”
BackgroundInfluentialHanahan, D. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62226-6 · Cited by 271
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 270 · cited 1×
“Drug resistance to targeted therapies in cancer can be classified as primary or acquired (Figure 1A) [8,9].”
BackgroundTargeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer
Salgia, R., & Kulkarni, P. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.01.001 · Cited by 264 · cited 2×
“Persistence in bacteria is the ability of a sub-clonal population of cells to survive treatment [51].”
BackgroundGoldman, A., Majumder, B., Dhawan, A., Ravi, S., Goldman, D., Kohandel, M., Majumder, P. K., & Sengupta, S. (2015) · Nature Communications · doi:10.1038/ncomms7139 · Cited by 260 · cited 1×
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
BackgroundHinohara, K., Wu, H.-J., Vigneau, S., McDonald, T. O., Igarashi, K. J., Yamamoto, K. N., Madsen, T., Fassl, A., Egri, S. B., Papanastasiou, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.014 · Cited by 255
Epigenetics as a mechanism driving polygenic clinical drug resistance
Glasspool, R. M., Teodoridis, J. M., & Brown, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603024 · Cited by 236 · cited 1×
“Meanwhile, other studies suggest that some persister phenotypes arise via plasticity induced by drug treatment [56,64,65].”
BackgroundBoshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4472 · Cited by 229 · cited 3×
“In melanoma cells, targeted therapy induced AXL expression, and co-treatment of AXL-expressing cells with an antibody–drug conjugate and MAPK inhibitors synergistically prevented tumor growth in melanoma patient-derived xenografts [80].”
BackgroundTargeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216 · cited 2×
“EGF816 PDCL FGFR signaling FGFR (BGJ398) [93]”
BackgroundSelf-citationPhenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216 · cited 1×
“For instance, epithelial-to-mesenchymal transition (EMT) is a phenotype switching event induced by targeted therapy in various tumors that has been linked to drug tolerance and/or resistance [78,79].”
BackgroundBlakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.012 · Cited by 204 · cited 3×
“HCC827, PDX NF-kB signaling NF-kB (PBS-1086) [90]”
BackgroundInfluentialMechanisms of Disease: Cancer stem cells--targeting the evil twin
Trumpp, A., & Wiestler, O. D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1110 · Cited by 199 · cited 1×
“Collectively, these studies support a model wherein a pre-existing sub-population of drug-tolerant tumor cells is enriched upon drug treatment, akin to the principle of non-genetic Darwinian selection [60,62,63].”
ResultDormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer
Vallette, F. M., Olivier, C., Lézot, F., Oliver, L., Cochonneau, D., Lalier, L., Cartron, P.-F., & Heymann, D. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.004 · Cited by 190 · cited 2×
“In cancer, the term “persister” has no clear biological definition and the term is used interchangeably with other terms such as tolerant [23,25,40], dormant [52], or quiescent [53] to refer to sub-populations of cancer cells that survive prolonged drug treatment [54].”
BackgroundA framework for understanding and targeting residual disease in oncogene-driven solid cancers
Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 181
Zawistowski, J. S., Bevill, S. M., Goulet, D. R., Stuhlmiller, T. J., Beltran, A. S., Olivares-Quintero, J. F., Singh, D., Sciaky, N., Parker, J. S., Rashid, N. U., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0653 · Cited by 180 · cited 2×
“Several studies have revealed that BET proteins facilitate chromatin remodeling and transcriptional adaptation necessary for establishing the DTP state in response to MEK and PI3K inhibitors in breast cancer models, which can be prevented by the BET inhibitor JQ1 [66,74].”
BackgroundNilsson, M. B., Sun, H., Robichaux, J., Pfeifer, M., McDermott, U., Travers, J., Diao, L., Xi, Y., Tong, P., Shen, L., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz4589 · Cited by 177
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Risom, T., Langer, E. M., Chapman, M. P., Rantala, J., Fields, A. J., Boniface, C., Alvarez, M. J., Kendsersky, N. D., Pelz, C. R., Johnson-Camacho, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05729-w · Cited by 174 · cited 3×
“Several studies have revealed that BET proteins facilitate chromatin remodeling and transcriptional adaptation necessary for establishing the DTP state in response to MEK and PI3K inhibitors in breast cancer models, which can be prevented by the BET inhibitor JQ1 [66,74].”
BackgroundA stress-induced early innate response causes multidrug tolerance in melanoma
Ravindran Menon, D., Das, S., Krepler, C., Vultur, A., Rinner, B., Schauer, S., Kashofer, K., Wagner, K., Zhang, G., Bonyadi Rad, E., et al. (2015) · Oncogene · doi:10.1038/onc.2014.372 · Cited by 170
Dravis, C., Chung, C.-Y., Lytle, N. K., Herrera-Valdez, J., Luna, G., Trejo, C. L., Reya, T., & Wahl, G. M. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.001 · Cited by 141 · cited 1×
“Beyond melanoma, SOX10 has been shown to mediate mammary duct cell state interconversion and promote de-differentiation to a more stem/progenitor state characterized by a neural crest-like phenotype in breast tumors [85].”
BackgroundA slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy
Sánchez-Danés, A., Larsimont, J.-C., Liagre, M., Muñoz-Couselo, E., Lapouge, G., Brisebarre, A., Dubois, C., Suppa, M., Sukumaran, V., del Marmol, V., et al. (2018) · Nature · doi:10.1038/s41586-018-0603-3 · Cited by 139 · cited 6×
“Drug-tolerant quiescent residual cells in basal cell carcinoma (BCC) can cause relapse after treatment is stopped [46,47].”
BackgroundInfluentialA cell identity switch allows residual BCC to survive Hedgehog pathway inhibition
Biehs, B., Dijkgraaf, G. J. P., Piskol, R., Alicke, B., Boumahdi, S., Peale, F., Gould, S. E., & de Sauvage, F. J. (2018) · Nature · doi:10.1038/s41586-018-0596-y · Cited by 137 · cited 3×
“Drug-tolerant quiescent residual cells in basal cell carcinoma (BCC) can cause relapse after treatment is stopped [46,47].”
BackgroundThe histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma
Banelli, B., Carra, E., Barbieri, F., Würth, R., Parodi, F., Pattarozzi, A., Carosio, R., Forlani, A., Allemanni, G., Marubbi, D., et al. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1090063 · Cited by 135 · cited 1×
“The second theme is that persisters are slow cycling, or alternatively termed dormant or quiescent, with little-to-no population growth [23,55].”
BackgroundSuppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 131 · cited 3×
“EGFR, ALK Erlotinib, crizotinib PC9 and xenograft, H3122 Dynamic transcriptional responses—remodeling of enhancers CDK7/12 (THZ1) [77]”
BackgroundMurakami, A., Takahashi, F., Nurwidya, F., Kobayashi, I., Minakata, K., Hashimoto, M., Nara, T., Kato, M., Tajima, K., Shimada, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086459 · Cited by 122
Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.153 · Cited by 112 · cited 1×
“Following the initial description by Settleman and colleagues, similar drug-tolerant persisters have been reported in many other cancer models, including lung cancer [35–40], melanoma [39–41], breast cancer [39,40,42], colon cancer [39], gastric cancer [43], ovarian cancer [40], leukemia [44], and glioblastoma [45].”
ResultLiu, L., Zhu, H., Liao, Y., Wu, W., Liu, L., Liu, L., Wu, Y., Sun, F., & Lin, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110225 · Cited by 103
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98 · cited 1×
“In the clinic this most closely corresponds to minimum residual disease (MRD), or the point of maximal tumor shrinkage prior to eventual tumor progression [8,27,28].”
BackgroundSong, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95
Self-citationNotch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Arasada, R. R., Shilo, K., Yamada, T., Zhang, J., Yano, S., Ghanem, R., Wang, W., Takeuchi, S., Fukuda, K., Katakami, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05626-2 · Cited by 93
Gong, K., Guo, G., Panchani, N., Bender, M. E., Gerber, D. E., Minna, J. D., Fattah, F., Gao, B., Peyton, M., Kernstine, K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0048-0 · Cited by 92
Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade
Lue, H.-W., Podolak, J., Kolahi, K., Cheng, L., Rao, S., Garg, D., Xue, C.-H., Rantala, J. K., Tyner, J. W., Thornburg, K. L., et al. (2017) · Genes & Development · doi:10.1101/gad.305292.117 · Cited by 89
Fan, W., Tang, Z., Yin, L., Morrison, B., Hafez-Khayyata, S., Fu, P., Huang, H., Bagai, R., Jiang, S., Kresak, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2668 · Cited by 83
Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer
Ishak, C. A., Classon, M., & De Carvalho, D. D. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.05.008 · Cited by 79 · cited 1×
“These elements are typically epigenetically repressed, but can become activated in cancers, in part due to decreases in DNA methylation [101].”
BackgroundHigh T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?
Ye, X., Zhu, Z.-Z., Zhong, L., Lu, Y., Sun, Y., Yin, X., Yang, Z., Zhu, G., & Ji, Q. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f691f · Cited by 79
Staberg, M., Rasmussen, R. D., Michaelsen, S. R., Pedersen, H., Jensen, K. E., Villingshøj, M., Skjoth‐Rasmussen, J., Brennum, J., Vitting‐Seerup, K., Poulsen, H. S., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12174 · Cited by 77 · cited 1×
“KDM2 [71], KDM3 [45], KDM5 [23,39,45,60,72], and KDM6 [45] have been found to be upregulated in different tumor models of drug tolerance and resistance to various drugs.”
BackgroundYoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 74 · cited 2×
“These include genetic drivers of drug resistance such as secondary mutations in the targeted oncogene, activation of bypass signaling pathways, and lineage transformation [10].”
BackgroundSelf-citationOct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells
Kobayashi, I., Takahashi, F., Nurwidya, F., Nara, T., Hashimoto, M., Murakami, A., Yagishita, S., Tajima, K., Hidayat, M., Shimada, N., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.064 · Cited by 70
Mechanisms of Metastatic Tumor Dormancy
Osisami, M., & Keller, E. T. (2013) · Journal of Clinical Medicine · doi:10.3390/jcm2030136 · Cited by 63
Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells
Keeratichamroen, S., Lirdprapamongkol, K., & Svasti, J. (2018) · Oncology Reports · doi:10.3892/or.2018.6258 · Cited by 61
Grassberger, C., McClatchy, D. M., Geng, C., Kamran, S. C., Fintelmann, F. J., Maruvka, Y. E., Piotrowska, Z., Willers, H., Sequist, L. V. D., Hata, A. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3652 · Cited by 55
Self-citationTumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma
Eberl, M., Mangelberger, D., Swanson, J. B., Verhaegen, M. E., Harms, P. W., Frohm, M. L., Dlugosz, A. A., & Wong, S. Y. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.015 · Cited by 53
Endo, H., Okami, J., Okuyama, H., Nishizawa, Y., Imamura, F., & Inoue, M. (2017) · Oncogene · doi:10.1038/onc.2016.431 · Cited by 50 · cited 2×
“In low oxygen conditions, cells activate hypoxia-inducible factors and upregulate the expression of key dormancy genes such as MIG6, resulting in a dormant and drug-resistant state [98].”
BackgroundInhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
Rothenberg, S. M., Concannon, K., Cullen, S. J., Boulay, G., Turke, A. B., Faber, A. C., Lockerman, E. L., Rivera, M. N., Engelman, J. A., Maheswaran, S., et al. (2015) · eLife · doi:10.7554/elife.06132 · Cited by 50
Drug persistence – From antibiotics to cancer therapies
Kochanowski, K., Morinishi, L., Altschuler, S. J., & Wu, L. F. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.03.003 · Cited by 36 · cited 1×
“To differentiate modes of survival from resistance and drug susceptibility, the expressions “tolerance” and “persistence” are used in bacteria [50].”
MethodHolden, D. W. (2015) · Science · doi:10.1126/science.1262033 · Cited by 34 · cited 1×
“Moreover, upon drug withdrawal, these drug-tolerant slow-cycling bacteria that survived antibiotic treatment can revert to a proliferative state and re-establish a drug sensitive population, demonstrating that bacterial drug persistence is transient and mediated by phenotypic plasticity rather than genetic alterations…”
BackgroundProteomic Analyses Identify a Novel Role for EZH2 in the Initiation of Cancer Cell Drug Tolerance
Pham, V., Pitti, R., Tindell, C. A., Cheung, T. K., Masselot, A., Stephan, J.-P., Guler, G. D., Wilson, C., Lill, J., Arnott, D., et al. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00773 · Cited by 26 · cited 3×
“HER2, EGFR Lapatinib SKBR Cell fate and lineage plasticity (increased methylation on K116 of Jarid2, stabilization, and recruitment to chromatin of the PRC2 complex) EZH2 (EPZ-6438) [86]”
BackgroundInfluential
Cited by
Senescence and cancer — role and therapeutic opportunities
Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity
Meier, P., Legrand, A. J., Adam, D., & Silke, J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00674-x · Cited by 382
“Moreover, non-mutational drug resistance mechanisms can also support the survival of residual cancer persister cells , which then serve as a reservoir from which tumours can re-emerge 5,6 .”
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02165-x · Cited by 246
Yang, Y., Li, S., To, K. K. W., Zhu, S., Wang, F., & Fu, L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03377-9 · Cited by 184
“A multifaceted array of factors, including driver oncogene mutations, epigenetic alterations, disruptions in critical signaling pathways, defects in the antigen-presenting pathway and immune evasion, are known to contribute to diminished effectiveness of immunotherapy [10–12].”
Metadata
- Authors
- Cabanos, H. F., & Hata, A. N.
- Affiliations
- Harvard University (US)
- Corresponding author
- Hata, Aaron N.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-05-28
- Volume
- 13
- Issue
- 11
- Pages
- 2666
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8198243
- OpenAlex
- W3164747206
- Semantic Scholar
- 2c8bf4ee4ae8fc459542c3b2c653293e06b91077
- Cited by
- 189
- References
- 131
- Citations by year
- 2026: 24 · 2025: 37 · 2024: 58 · 2023: 43 · 2022: 25 · 2021: 2
- FWCI
- 4.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (K08 CA197389, R01 CA137008)
- Doris Duke Charitable Foundation (Clinical Scientist Development Award)
- Stand Up To Cancer (Convergence 1.0 Team Award)
- V Foundation (Scholar Award)
- Ludwig Center at Harvard (N/A)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- drug-tolerant persister cells, targeted therapy, drug resistance, minimal residual disease, lung cancer, tumor dormancy, tumor recurrence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.